BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Clavis Reviews 'Strategic Options' After Phase III Bomb
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Clavis Reviews 'Strategic Options' After Phase III Bomb
April 2, 2013
By
Nuala Moran
No Comments
Clavis Pharma AS has been hit by the Phase III failure of elacytarabine, its lipid-enhanced version of cytarabine, in a 380-patient trial in advanced acute myeloid leukemia (AML).
BioWorld